

Non Muscle Invasive Bladder Cancer (NMIBC)– Pipeline Insight, 2020

<https://marketpublishers.com/r/N8260197F3C3EN.html>

Date: September 2020

Pages: 90

Price: US\$ 2,000.00 (Single User License)

ID: N8260197F3C3EN

Abstracts

This report can be delivered to the clients within 72 - 96 Hours

DelveInsight's, "Non Muscle Invasive Bladder Cancer (NMIBC)– Pipeline Insight, 2020," report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Non-Muscle Invasive Bladder Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Non Muscle Invasive Bladder Cancer Understanding

Non Muscle Invasive Bladder Cancer: Overview

NMIBC is defined as a superficial neoplasia confined to the mucosa, (including Ta which is a noninvasive papillary carcinoma and carcinoma in situ (CIS), which is flat and non-papillary) or lamina propria (T1) based on the American Joint Committee on Cancer (AJCC) staging system, also known as the tumor node metastases (TNM) classification. Ta accounts for most NMIBC (60%), whereas T1 and Tis (CIS) account for 30% and 10%, respectively.

Symptoms

Some people may have symptoms that suggest they have bladder cancer. Others may feel nothing at all. Some symptoms should never be ignored. Some of the common symptoms are:

Hematuria (blood in the urine) - the most common symptom, often without pain

Frequent and urgent urination

Pain when urine passes

Pain in lower abdomen

Back pain

Diagnosis

The following tests may be done to determine bladder cancer:

Urine cytology: The color and content of the urine will be checked. This test will also look at body cells under a microscope to test for cancer cells.

Blood tests: A comprehensive metabolic panel (CMP), which includes kidney and liver function tests

A. Computerized tomography scan (also known as CT or CAT scans) with a bladder scope 'cystoscopy' are often good enough to diagnose bladder cancer.

Cystoscopy: A doctor will use a thin tube that has a light and camera at the end of it (cystoscope) to pass through the urethra into the bladder.

Treatment

The main treatments for when the cancer cells are found only in the bladder's inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Superficial, non-muscle invasive bladder cancers (NMIBCs) are

managed with cystoscopic transurethral resection of all visible lesions followed by intravesical chemotherapy and/or immunotherapy. Pembrolizumab is approved for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy

Non Muscle Invasive Bladder Cancer Emerging Drugs Chapters

This segment of the Non Muscle Invasive Bladder Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Non Muscle Invasive Bladder Cancer Emerging Drugs

Opdivo: Bristol-Myers Squibb/Ono Pharmaceuticals

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body's own immune system to help restore anti-tumor immune response by blocking the interaction between PD-1 and its ligands. By harnessing the body's own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers. It is currently in phase III stage of development.

UGN-102: UroGen Pharma

UGN-102 (mitomycin gel) is an investigational formulation that utilizes our innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. Administered locally via standard catheters, UGN-102 is designed to fill and conform to the anatomy of the bladder and dwell for a period of several hours before being excreted via normal urine flow. UroGen has completed enrollment in a phase 2b study to further investigate UGN-102 for the treatment of intermediate-risk low-grade NMIBC.

Further product details are provided in the report.....

Non Muscle Invasive Bladder Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Non Muscle Invasive Bladder Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Non-Muscle Invasive Bladder Cancer

There are approx. 25+ key companies which are developing the therapies for Non Muscle Invasive Bladder Cancer. The companies which have their Non Muscle Invasive Bladder Cancer drug candidates in the most advanced stage, i.e. phase III include, Bristol-Myers Squibb/Ono Pharmaceuticals.

Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Non Muscle Invasive Bladder Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Non Muscle Invasive Bladder Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non Muscle Invasive Bladder Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger,

licensing along with a thorough therapeutic assessment of emerging Non Muscle Invasive Bladder Cancer drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Non Muscle Invasive Bladder Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Non Muscle Invasive Bladder Cancer.

In July 2014, Bristol-Myers Squibb Company and Ono Pharmaceutical had signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan.

In April 2020, UroGen Pharma announced positive interim data analysis of UGN-102 (mitomycin) for intravesical solution in patients with low-grade intermediate risk non-muscle invasive bladder cancer (LG IR-NMIBC). These data were featured in a late-breaking abstract published in the April Supplement to The Journal of Urology. The detailed results presentation will be available online via the American Urological Association (AUA) in mid-May 2020.

Non Muscle Invasive Bladder Cancer Report Insights

Non Muscle Invasive Bladder Cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Non Muscle Invasive Bladder Cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Non Muscle Invasive Bladder Cancer drugs?

How many Non Muscle Invasive Bladder Cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non Muscle Invasive Bladder Cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Non Muscle Invasive Bladder Cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Non Muscle Invasive Bladder Cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Viventia Bio

Viralytics

Vaxiion Therapeutics

UroGen Pharma Ltd.

EMD Serono

AstraZeneca

Hoffmann-La Roche

Theralase Inc

Telormedix

Taris Biomedica

Spectrum Pharmaceuticals

Incyte Corporation

Rapamycin Holding

Pfizer

NanOlogy

Merck Sharp & Dohme Corp.

Lipac Oncology

Jiangsu Yahong Meditech Co.,Ltd.

Janssen Research & Development, LLC

Hoffmann-La Roche

Handok

Hamlet Pharma AB

Halozyme Therapeutics

Apices Soluciones

FKD Therapies

H3 Biomedicine Inc.

CG Oncology, Inc.

Bioniche Life Sciences Inc.

BioCis Pharma

Asieris Pharmaceutical

Archivel Farma

Altor BioScience

Aadi,

Key Products

Vicinium

Instiladrin

PF-06801591

Atezolizumab

APL 1202

Imfinzi

Opdivo

Apaziquone

CG0070

Inodiftagene vixteplasmid

Balversa

LiPax (paclitaxel)

Pemigatinib

TLD 1433

ALT-803

Lenalidomide

UGN-102

ABI-009

ALT-801

Alpha1H

NanoDoce

HS-410

Avelumab

BGJ398

UGN-201

TAR 200

E7766

VAX014

Cavatak

UGN-302

ATX 101

TL-532

Bladder Cancer Program

Contents

Introduction

Executive Summary

Non Muscle Invasive Bladder Cancer: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Non Muscle Invasive Bladder Cancer – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Non Muscle Invasive Bladder Cancer companies' collaborations, Licensing,
Acquisition -Deal Value Trends

Non Muscle Invasive Bladder Cancer Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Opdivo: Bristol-Myers Squibb/Ono Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Mid Stage Products (Phase II)

Comparative Analysis

UGN-102: UroGen Pharma

Product Description

Research and Development

Product Development Activities

Inodiftagene Vixteplasmid: Anchiano Therapeutics

Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Early Stage Products (Phase I)
Comparative Analysis
TAR 200: TARIS Biomedical
Product Description
Research and Development
Product Development Activities
E7766: H3 Biomedicine
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Pre-clinical and Discovery Stage Products
Comparative Analysis
UGN-302: UroGen Pharma
Product Description
Research and Development
Product Development Activities
ATX 101: APIM Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
Non Muscle Invasive Bladder Cancer Key Companies
Non Muscle Invasive Bladder Cancer Key Products
Non Muscle Invasive Bladder Cancer- Unmet Needs
Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
Non Muscle Invasive Bladder Cancer Analyst Views
Non Muscle Invasive Bladder Cancer Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Non Muscle Invasive Bladder Cancer

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Non Muscle Invasive Bladder Cancer

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Non Muscle Invasive Bladder Cancer (NMIBC)– Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/N8260197F3C3EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N8260197F3C3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970